Talks · Panels · Long-form
Practical operator content for biotech, regulatory, and family office audiences. Available for keynotes, panels, university lectures, podcasts.
For biotech founders, regulatory counsel, and capital allocators. Why most cell-derived therapeutic programs land on the wrong side of FDA jurisdiction. CMC, manufacturing controls, and the cost of misclassification. 45 minutes plus Q&A.
For LPs, family office principals, biotech operators. Why patient capital fits regulated biotech better than venture timelines. Structuring investment milestones to FDA decision points rather than fundraising rounds.
For healthcare operators, in-house counsel, and CFOs. Documentation patterns and operating signals that show up before federal action. HIPAA, AKS, Stark, OIG, and what thirty years inside FDA-regulated ventures has taught.
For oncology audiences, clinicians, and biotech investors. The mechanism behind TOL, the an academic medical foundation partnership, and what it means for chemotherapy-free oncology.
For Dallas civic, university, and ecosystem audiences. The Dallas biotech network, Methodist, UT Southwestern, and why this is the place to build regulated healthcare today.
Available for keynote talks, panel participation, and fireside conversation formats. Strong fit for biotech, regulatory, and family office events.
Available for university guest lectures, particularly at SMU, UT Arlington, UT Dallas, and Texas A&M Health Science Center. No fee for student-facing engagements.
Open to long-form podcast and interview formats. No publicist filter, direct response. Preference for shows that go past the surface.
Available for press commentary on FDA biologics policy, exosome regulatory science, frontier oncology, and healthcare compliance. Quotes attributed and verified.